Sichuan Huiyu Pharmaceutical Co., Ltd.

SHSE:688553 Stock Report

Market Cap: CN¥6.6b

Sichuan Huiyu Pharmaceutical Balance Sheet Health

Financial Health criteria checks 6/6

Sichuan Huiyu Pharmaceutical has a total shareholder equity of CN¥3.9B and total debt of CN¥675.3M, which brings its debt-to-equity ratio to 17.4%. Its total assets and total liabilities are CN¥5.0B and CN¥1.2B respectively. Sichuan Huiyu Pharmaceutical's EBIT is CN¥87.6M making its interest coverage ratio -1.7. It has cash and short-term investments of CN¥2.7B.

Key information

17.4%

Debt to equity ratio

CN¥675.30m

Debt

Interest coverage ratio-1.7x
CashCN¥2.72b
EquityCN¥3.88b
Total liabilitiesCN¥1.17b
Total assetsCN¥5.05b

Recent financial health updates

Recent updates

Sichuan Huiyu Pharmaceutical's (SHSE:688553) Promising Earnings May Rest On Soft Foundations

Nov 02
Sichuan Huiyu Pharmaceutical's (SHSE:688553) Promising Earnings May Rest On Soft Foundations

Sichuan Huiyu Pharmaceutical Co., Ltd. (SHSE:688553) Stock Catapults 38% Though Its Price And Business Still Lag The Market

Oct 29
Sichuan Huiyu Pharmaceutical Co., Ltd. (SHSE:688553) Stock Catapults 38% Though Its Price And Business Still Lag The Market

Here's Why Sichuan Huiyu Pharmaceutical (SHSE:688553) Can Manage Its Debt Responsibly

Sep 29
Here's Why Sichuan Huiyu Pharmaceutical (SHSE:688553) Can Manage Its Debt Responsibly

Sichuan Huiyu Pharmaceutical (SHSE:688553) Has A Pretty Healthy Balance Sheet

Jun 07
Sichuan Huiyu Pharmaceutical (SHSE:688553) Has A Pretty Healthy Balance Sheet

Sichuan Huiyu Pharmaceutical Co., Ltd.'s (SHSE:688553) 33% Share Price Surge Not Quite Adding Up

Mar 07
Sichuan Huiyu Pharmaceutical Co., Ltd.'s (SHSE:688553) 33% Share Price Surge Not Quite Adding Up

Financial Position Analysis

Short Term Liabilities: 688553's short term assets (CN¥3.1B) exceed its short term liabilities (CN¥1.1B).

Long Term Liabilities: 688553's short term assets (CN¥3.1B) exceed its long term liabilities (CN¥44.5M).


Debt to Equity History and Analysis

Debt Level: 688553 has more cash than its total debt.

Reducing Debt: 688553's debt to equity ratio has reduced from 24.8% to 17.4% over the past 5 years.

Debt Coverage: 688553's debt is well covered by operating cash flow (30.9%).

Interest Coverage: 688553 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 12:29
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sichuan Huiyu Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution